Skip to main content
Caplight Logo









Leman Biotech

Leman Biotech

Private
ShenzhenHealthcare & Life Scienceshttps://lemanbio.com/

Last Round

Series A

Extension

Mar 4, 2026

Total Funding Raised

$60M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Leman Biotech is a biotechnology company that develops next-generation metabolic cancer immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cancer immunotherapymetabolic immunotherapyCAR-T therapycell therapymetabolic reprogrammingAI drug discoveryAI biotechclinical-stage biotechT-cell exhaustionarmored CAR-TTIL therapysolid tumor therapyautoimmune disease therapysystemic lupus erythematosusSLE

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Leman Biotech Comparables

Compare Leman Biotech with similar companies based on industry and business-model similarity.

Leman Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ucello Biotechnology
82%
CARsgen Therapeutics
77%
IASO Bio
76%

Leman Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 4, 2026
Series ANov 13, 2024
AngelJun 18, 2024
AngelJan 18, 2022

Leman Biotech Investors

Notable investors and investment history

Leman Biotech investors
InvestorRounds
中山创业投资有限公司Series A Extension
Fuhui Venture CapitalAngel
Tiantu CapitalAngel
Tailong InvestmentSeries A Extension
5Y CapitalAngel
Zhongshan Venture Capital Co., Ltd.Series A Extension
Yuecai Zhongyin Private Equity Fund ManagementSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2026

    Grew 100% QoQ from 3 to 6 employees.

  • Mar 4, 2026

    $28M round led by XtalPi and Yuecai Zhongyin.

Leman Biotech Filings

Explore SEC and related filing metadata, where available.

Leman Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Leman Biotech's valuation, stock price, and market status.

Is Leman Biotech a public or private company?

Leman Biotech is a private company.

What is the current stock price of Leman Biotech?

Leman Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Leman Biotech worth (valuation)?

Valuation information for Leman Biotech is not publicly available.

Can I buy Leman Biotech stock?

Leman Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Leman Biotech's last funding round?

Leman Biotech's most recent funding round was Series A Extension on March 4, 2026.

Who are the main investors in Leman Biotech?

Key investors in Leman Biotech include Tiantu Capital, Yuecai Zhongyin Private Equity Fund Management.

Will Leman Biotech IPO soon?

No public IPO plans have been announced for Leman Biotech.

How can I track Leman Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Leman Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShenzhen
Employee Range6
Year Founded2021
Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?